The effects of vaginal atrophy

Vaginal atrophy is very common in women who have gone through the menopause- about half will experience pain and discomfort.1,2

Unsurprisingly, vaginal atrophy can have wide-ranging effects on patients, with impacts on their well-being, quality of life, body image and relationships.1,2

Barriers remain for women who want to discuss their condition, as even if they want to ask for accurate medical information about vaginal atrophy, they may still want their doctor to start the conversation.3

Vaginal atrophy is very common in women who have gone through the menopause- about half will experience pain and discomfort.1,2

Unsurprisingly, vaginal atrophy can have wide-ranging effects on patients, with impacts on their well-being, quality of life, body image and relationships.1,2

Barriers remain for women who want to discuss their condition, as even if they want to ask for accurate medical information about vaginal atrophy, they may still want their doctor to start the conversation.3

My Blissel® Time to talk
Video Library

A library of discussions led by national experts Dr Anne Connolly, Dr Diana Mansour and Nurse Specialist Consultant Nikki Noble.
The videos cover a range of very useful, relevant and important topics including, the signs and symptoms of VA, how to make the diagnosis and the impact of vaginal atrophy on a patients quality of life.

Challenges in vaginal atrophy diagnosis
(signs and symptoms)

Women can be reluctant to talk to their doctor about their vaginal symptoms for many reasons, which can include:4
• Embarrassment
• Feeling that nothing can be done
• Thinking that the topic is inappropriate to discuss

Women can be reluctant to talk to their doctor about their vaginal symptoms for many reasons, which can include:4
• Embarrassment
• Feeling that nothing can be done
• Thinking that the topic is inappropriate to discuss
Diagnosis may be complicated by the fact that women with vaginal atrophy can present with a variety of symptoms.5

Vaginal dryness

Dyspareunia

Itching

Dysuria

Burning

Prescribe Blissel® by brand for your patients.

Vaginal atrophy treatment

NICE guidelines state local treatment is preferable to systemic hormonal replacement therapy for vaginal symptoms, with vaginal oestrogen suggested to be offered to women to treat the symptoms of vaginal atrophy.6

Despite clear guidelines from NICE, 50% of postmenopausal women with genitourinary symptoms have never used any therapy for this problem.7

Treating vaginal atrophy with Blissel®

Blissel® is an ultra low dose estriol vaginal gel containing 50 micrograms per dose (1 gram) of estriol, which is indicated for treating the symptoms of vaginal atrophy due to oestrogen deficiency in postmenopausal women.9,10

The treatment is well tolerated and effective for postmenopausal vaginal atrophy.10

When you prescribe Blissel® your patients may notice a rapid improvement in symptoms from the initial days of treatment.8

Upcoming Webinars 2024

6th Feb

7pm to
8:30pm

Troubleshooting common menopause issues
with Dr Julie Oliver – G.P with extended role from Durham

Join us for an informative discussion about troubleshooting common menopause issues.

To register your interest please click below:

How Blissel
Works

Efficacy

Dosing

Ultra low dose estriol vaginal gel9,10

Prescribing and Adverse event reporting information for Blissel can be found here.

 Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Consilient Health (UK) Ltd, No. 1 Church Road, Richmond upon Thames, Surrey TW9 2QE UK or drugsafety@consilienthealth.com 

1. Nappi RE, Palacios S. Climacteric. 2014;17:3–9. 2. Moral E, et al. Menopause. 2018;25(12):1418-23. 3. Krychman M, et al. J Sex Med 2017;14:425-433. 4. Kagan R, et al. Drugs Aging. 2019;36:897–908. 5. Palmaa F, et al. Maturitas. 2018;108:18–23. 6. NICE. Menopause: diagnosis and management (NG23). Available from: https://www.nice.org.uk/guidance/ng23/chapter/recommendations. Accessed December 2023. 7. NAMS position statement. Menopause. 2020;27(9):976-92. 8. Lázaro-Carrasco de la Fuente J, et al. J Menopausal Med. 2022;28(2):60-69. 9. Blissel 50 micrograms/g vaginal gel. Summary of product characteristics. 10. Cano A, et al. Menopause. 2012;19(10):1130-9.

Date of preparation: Jan 2024 | UK-BLS-291x